What is it about?
In this review, we will discuss the efficacy of the different targeting approaches used for targeted drug delivery to malignant cells by Nanoparticles (NPs).
Featured Image
Why is it important?
The most important advantages of NPs for cancer therapy include their stability, high carrier capacity, the ability to load with both hydrophilic and hydrophobic drugs, controlled drug release, and variable routes of administration. It is also possible to load multiple drugs at the same time and monitor NPs in the body. Reducing the administration dose of current anti-cancer therapeutic agents is one of the main goals of several investigators, to date. Application of various NPs could partially help to reach this goal.
Perspectives
Several ligands against various tumor biomarkers have tested for specific drug delivery into tumor tissues. Among them, TfRs, CPPs, LDLRs, integrins, carbohydrates (lectin ligands), EGFRs, and FRs are extensively studied for specific drug delivery into cancer tissues. However, very limited studies are performed on humans in clinical trials. Moreover, there is no comprehensive study regarding the comparison of various targeting molecules in the same pathologic condition. Therefore, it is necessary to design the comparative studies accompanied by initial clinical trials in various cancer diseases to reach a rational decision.
Hamed Mohammadi
Read the Original
This page is a summary of: Nanoparticles and targeted drug delivery in cancer therapy, Immunology Letters, October 2017, Elsevier,
DOI: 10.1016/j.imlet.2017.07.015.
You can read the full text:
Contributors
The following have contributed to this page
